Gilead Sciences on Thursday reported flat second-quarter earnings on slightly higher revenue and raised its full-year ...

Access is the central tenet to the success of lenacapavir as a form of preexposure prophylaxis (PrEP), according to Jeremiah Johnson, the executive director of PrEP4All and Mitchell Warren, the ...

Amid the questions about the Yeztugo rollout, Gilead’s second quarter performance offered some reassurance about the company’s broader business.

Gilead Sciences Inc. lifted its full-year outlook after strong HIV drug sales in the second quarter helped revenue and ...

Gilead Sciences on Thursday reported flat quarterly earnings on slightly higher revenue and raised its full-year financial ...

The government has canceled nearly $500 million in research grants into the revolutionary technology, which experts believe ...

Lagos State Governor, Babajide Sanwo-Olu, has called on state legislatures across the country to prioritise the passage and ...

Unfinished Business' is a powerful documentary that revisits the lives of older African American women living with HIV, ...

A Maryland nonprofit that has received $56 million taxpayer dollars faces a series of transparency concerns from accounting ...

UConn Health Disparities Institute share their insights about the national Black Women First Initiative and the path forward ...

A man pled guilty to murdering his 73-year-old lover, burying him in a bathtub full of concrete, and treating the victim's ...